浙江大学学报（医学版）2026，Vol.55Issue(4)：364-372,9.DOI:10.3724/zdxbyxb-2025-0587
泰它西普在风湿病和自身免疫病中的应用研究进展
Research progress on the application of telitacicept in rheumatism and autoimmune diseases
摘要
Abstract
Traditional treatment regimens for rheumatism and autoimmune diseases are associated with significant adverse effects,and some patients have a limited response,leading to poor prognosis.Telitacicept,a biologic agent and fusion protein targeting B cell activating factor(BAFF)and a proliferation inducing ligand(APRIL),offers a novel therapeutic strategy for refractory rheumatism and autoimmune diseases.Clinical trials have shown promising efficacy and safety.In systemic lupus erythematosus,telitacicept reduces disease activity and facilitates glucocorticoid sparing,with favorable outcomes also observed in pediatric patients.In Sjögren's syndrome,telitacicept achieves sustained improvement in clinical symptoms and disease activity.In rheumatoid arthritis,telitacicept improves the response rates for the American College of Rheumatology 20%improvement criteria(ACR20)and for the American College of Rheumatology 50%improvement criteria(ACR50)while significantly reducing glucocorticoid requirements.In IgA vasculitis,studies focused on patients with renal involvement,and showed efficacy in reducing proteinuria in both adults and children.In myasthenia gravis,telitacicept reduces disease severity and improves quality of life.Additionally,telitacicept has shown preliminary therapeutic potential in IgG4-related disease and granulomatosis with polyangiitis,warranting further investigation.Existing clinical data indicate a favorable overall safety profile for telitacicept.However,attention should be paid to long-term risks of infection,decreased immunoglobulin levels,potential resistance mechanisms,and its efficacy and safety in special populations.This review summarizes recent research progress on the use of telitacicept in rheumatism and autoimmune diseases,aiming to provide a reference for its clinical application.关键词
风湿病/自身免疫病/泰它西普/B细胞活化因子/增殖诱导配体/综述Key words
Rheumatism/Autoimmune disease/Telitacicept/B cell activating factor/A proliferation-inducing ligand/Review分类
医药卫生引用本文复制引用
王雪,许艺怀,童桂霞,张洪霞..泰它西普在风湿病和自身免疫病中的应用研究进展[J].浙江大学学报（医学版）,2026,55(4):364-372,9.基金项目
济南市卫生健康委员会科技发展计划(2024304010)This study was supported by Science and Technology Development Program of Jinan Municipal Health Commission(2024304010) （2024304010）
